Increased immunosuppressive vulnerability in elderly renal transplant recipients

Transplantation

Volumn 69, Issue 5, 2000, Pages 885-889

  Meier Kriesche, Herwig Ulf ^a   Ojo, Akinlolu ^a   Hanson, Julie ^a   Cibrik, Diane ^a   Lake, Kathleen ^a   Agodoa, Lawrence Y ^a   Leichtman, Alan ^a   Kaplan, Bruce ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; FATALITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0034653643     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200003150-00037     Document Type: Article

References (27)

1. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
2. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436.
3. Miller J, Pirsch JD, Deierhoi M, Vincenti F, Filo RS. FK 506 in kidney transplantation: results of the USA randomized comparative phase III study: the FK 506 kidney transplant study group. Transplant Proc 1997; 29: 304.
4. Preston R, Ball S, Cairns T, et al. FK 506 as primary immunosuppressive therapy in renal transplantation. Transplant Proc 1998; 30: 1214.
5. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. (Sirolimus European Renal Transplant Study Group). Transplantation 1999; 67: 1036.
6. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040.
7. Laskow DA, Neylan JF, Shapiro RS, Pirsch JD, Vergne-Marini PJ, Tomlanovich SJ. The role of tacrolimus in adult kidney transplantation: a review. Clin Transplant 1998; 12: 489.
8. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomized trials. BMJ 1999; 318: 1104.
9. Schaubel D, Desmeules M, Mao Y, Jeffery J, Fenton S. Survival experience among elderly end-stage renal disease patients: a controlled comparison of transplantation and dialysis. Transplantation 1995; 60: 1389.
10. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
11. The U.S. Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. Transplant Proc 1997; 29: 348.
12. Danovitch GM. Mycophenolate mofetil in renal transplantation: results from the U.S. randomized trials. Kidney Int Suppl 1995; 52:S93-6.
13. Tersigni R, Kjellstrand CM, Simmons RL, Najarian JS. Renal transplantation in high-risk patients older than sixty years. Am J Surg 1976; 131: 648.
14. Wedel N, Brynger H, Blohme I. Kidney transplantation in patients 60 years and older. Scand J Urol Nephrol Suppl 1980; 54: 106.
15. Pirsch JD, Stratta RJ, Armbrust MJ, et al. Cadaveric renal transplantation with cyclosporine in patients more than 60 years of age. Transplantation 1989; 47: 259.
16. Cantarovich D, Baatard R, Baranger T, et al. Cadaveric renal transplantation after 60 years of age: a single center experience. Transplant Int 1994; 7: 33.
17. Ismail N, Hakim RM, Helderman JH. Renal replacement therapies in the elderly. Part II. Renal transplantation. Am J Kidney Dis 1994; 23: 1.
18. Hestin D, Frimat L, Hubert J, Renoult E, Huu TC, Kessler M. Renal transplantation in patients over sixty years of age. Clin Nephrol 1994; 42: 232.
19. Jassal SV, Opelz G, Cole E. Transplantation in the elderly: a review. Geriatr Nephrol Urol 1997; 7: 157.
20. Nyberg G, Nilsson B, Norden G, Karlberg I. Outcome of renal transplantation in patients over the age of 60: a case-control study. Nephrol Dial Transplant 1995; 10: 91.
21. Meier-Kriesche H-U, Friedman G, Mulgaonkar S, Jacobs M, Kaplan B. Infectious complications in elderly transplant recipients. Transplantation 1999; 68: 1294.
22. Solana R, Alonso MC, Pena J. Natural killer cells in healthy aging. Exp Gerontol 1999; 34: 435.
23. Pawelec G, Wagner W, Adibzadeh M, Engel A. T cell immunosenescence in vitro and in vivo. Exp Gerontol 1999; 34: 419.
24. Borrego F, Alonso MC, Galiani MD, et al. NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol 1999; 34: 253.
25. Onsrud M. Age dependent changes in some human lymphocyte sub-populations. Changes in natural killer cell activity. Acta Pathol Microbiol Scand [C] 1981; 89: 55.
26. Krishnaraj R, Blandford G. Age-associated alterations in human natural killer cells. 2. Increased frequency of selective NK subsets. Cell Immunol 1988; 114: 137.
27. Chakraborty A, Chakraborty NG, Chattopadhyay U. Age-related natural killer activity of peripheral blood lymphocytes from healthy subjects and cancer patients: a comparative in vitro study with interleukin-2. Tumori 1994; 80: 233.